Investor Presentaiton

India Business - Sales ramp-up Leadership in chronic segment; Strong positioning in acute segment 30 brands in top 300 brands of country 7 10 FY05 FY06 10 year CAGR 26% 112 12 15 20 20 17 24 29 20 Sales in Rs Billion Therapeutic Revenue Break-up 30 37 FY13 FY14 FY15* FY05 - FY14 numbers exclude Ranbaxy financials * FY15 numbers include the impact of Ranbaxy merger © Sun Pharmaceutical Industries Limited. All Rights Reserved. 67 Others, 6% Opthalmology, 3% Neuro-Psychiatry, 18% Respiratory, 4% Dermatology, 4% Gynaecology, 4% Vitamins/ Minerals / Nutrients, 4% Pain / Analgesics, 7% Ophthalmology 9% SUN PHARMA Market Share 8.9% Cardiology, 17% Anti-Infective 12% Gastroenterology, 12% As per AIOCD AWACS - Sept'15 23

View entire presentation